BIO-Europe 2026
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to BIO-Europe 2026 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
About this event
Bio Innovations Europe 2026
Event type: Biotechnology, Bioinnovation, Life Sciences, Biopharma, R&D, Industrial Biotech, Sustainability, Advanced Materials, Commercialization, Startup/Investor Networking
Estimated attendance: Approximately 2,000 to 6,000 attendees, depending on final agenda, co-located meetings, exhibitor participation, and whether the event includes a strong startup, investor, or partnering program.
Bio Innovations Europe 2026 is positioned as a high-value B2B event for the biotechnology and life sciences ecosystem. It is not just a scientific conference; it is also a commercial and partnership-driven meeting place where buyers, innovators, technology providers, investors, research teams, and industry stakeholders come together to discuss new products, platform technologies, research collaboration, scale-up, and market access.
For attendee-list selling, this kind of event is especially attractive when your client is targeting decision-makers in biotechnology, pharmaceuticals, healthcare innovation, lab technologies, industrial biotech, sustainability-driven manufacturing, and research services. The most valuable contacts are usually not only scientists, but also business leaders, innovation heads, partnership managers, procurement teams, R&D leaders, and commercialization executives.
1️⃣ Who attends: Buyers / Attendees
This event typically attracts a mix of scientific, commercial, and investment audiences. The buyer value is strongest among attendees who influence purchasing, partnership decisions, vendor selection, technology adoption, or research collaboration.
Main attendee groups likely include:
- Biotech founders, CEOs, and COOs from early-stage and growth-stage companies
- R&D leaders, innovation managers, and scientific directors
- Business development, licensing, and strategic partnership executives
- Pharma innovation teams and open-innovation managers
- Laboratory managers, procurement teams, and technical operations leaders
- Investors, venture capital teams, and corporate development professionals
- University tech-transfer officers and research commercialization specialists
- Government and public-sector innovation stakeholders
- Service providers in lab equipment, diagnostics, contract research, software, and analytics
- Manufacturing and sustainability leaders exploring industrial biotech applications
The strongest buyer layer is usually the combination of biotech companies, pharma innovation teams, life-science service providers, lab technology buyers, and research institutions with budgets for new tools, software, assays, services, and partnerships.
2️⃣ Where the show is happening + attendee geographic origin
Venue: If the event has not yet publicly confirmed a final location, it should be treated as a Europe-based biotech conference with a pan-European audience. Once the venue is confirmed, location targeting can be refined by city, country, and regional catchment.
Likely attendee origin: Primarily Europe, with attendance from the United Kingdom, Germany, France, the Netherlands, Switzerland, Belgium, Ireland, Spain, Nordics, and Central Europe. Depending on the speaker and sponsor mix, international visitors may also come from North America, the Middle East, and parts of Asia-Pacific.
This event is usually best treated as a regional-to-global European business event, because biotech innovation is a cross-border industry and many delegates attend specifically to source technologies, form partnerships, and evaluate market opportunities across multiple countries.
3️⃣ Audience reach: Local / National / Global
Reach type: Global with a strong European core.
Bio innovation events in Europe often have a global reputation even when the physical attendance is concentrated in Europe. That means the audience may be geographically regional, but commercially the event reaches a much broader international market. This makes it useful for clients selling:
- Biotech products and services
- Lab instruments and consumables
- Clinical research and CRO services
- Software platforms for life sciences
- Drug discovery and analytics solutions
- Industrial biotech, sustainability, and fermentation technologies
4️⃣ Sample buyer company names + websites
Below is a targeted sample buyer table of companies that are likely to be relevant for attendee-list sales around Bio Innovations Europe 2026. These are selected based on their fit with biotechnology, life sciences, R&D, diagnostics, pharma innovation, lab operations, and commercial partnerships.
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Roche | roche.com | Head of Innovation Partnerships / Director, Business Development | Major life sciences player with strong interest in biotech partnerships, diagnostics, and innovation sourcing. |
| 2 | Novartis | novartis.com | External Innovation Lead / R&D Portfolio Manager | Strong buyer profile for pipeline partnerships, open innovation, and emerging biotech opportunities. |
| 3 | Sanofi | sanofi.com | Alliance Manager / New Product Innovation Director | Relevant for biotech sourcing, clinical pipeline discussions, and strategic partnerships. |
| 4 | GSK | gsk.com | Partnering Manager / Scientific Collaboration Lead | Likely to attend for innovation scouting, licensing, and research collaboration. |
| 5 | AstraZeneca | astrazeneca.com | Director, External Science / Innovation Strategy Manager | Very strong fit for biotech commercialization, research partnerships, and therapeutic innovation. |
| 6 | Bayer | bayer.com | Innovation Partnering Lead / R&D Strategy Manager | Useful for healthcare, crop science, and industrial biotech applications. |
| 7 | Merck Group | merckgroup.com | Business Development Manager / Lab Solutions Director | Strong buyer for life science tools, reagents, analytics, and research technologies. |
| 8 | Thermo Fisher Scientific | thermofisher.com | Product Marketing Director / Strategic Accounts Manager | Highly relevant for lab instrumentation, consumables, workflow platforms, and research buyers. |
| 9 | Illumina | illumina.com | Regional Sales Director / Genomics Partnerships Manager | Excellent fit for genomics, sequencing, precision medicine, and research lab buyers. |
| 10 | QIAGEN | qiagen.com | Commercial Director / Global Alliances Manager | Relevant for sample prep, molecular diagnostics, and biotech research markets. |
| 11 | Lonza | lonza.com | Head of Business Development / CDMO Partnership Lead | Strong fit for contract development, manufacturing, and biotech scale-up discussions. |
| 12 | Evotec | evotec.com | Alliance Director / External Innovation Manager | Likely buyer for biotech services, discovery platforms, and collaboration opportunities. |
| 13 | bioMérieux | biomerieux.com | Product Manager / Global Marketing Director | Strong fit for diagnostics, lab workflows, and clinical microbiology buyers. |
| 14 | Genmab | genmab.com | Partnering Manager / Director, Translational Research | Relevant for antibody innovation, pipeline growth, and research collaboration. |
| 15 | Abcam | abcam.com | Commercial Strategy Lead / Life Science Sales Manager | Strong buyer for research tools, reagents, and scientific customer engagement. |
| 16 | Oxford Nanopore Technologies | nanoporetech.com | Partnerships Director / Regional Business Manager | Excellent fit for advanced sequencing, research adoption, and innovation-focused buyer groups. |
| 17 | BioNTech | biontech.com | Head of Alliance Management / Innovation Sourcing Lead | High-value biotech buyer with strong interest in discovery, therapeutics, and ecosystem partnerships. |
| 18 | Sartorius | sartorius.com | Business Development Director / Lab Product Manager | Very strong fit for bioprocessing, lab equipment, and life sciences manufacturing buyers. |
Top 5 priority buyer companies for first outreach: Roche, Thermo Fisher Scientific, AstraZeneca, Lonza, and Sartorius. These represent a strong mix of pharma, biotech, lab tools, and bioprocessing demand.
5️⃣ Job profiles, industries & event type
For this event, the best buyer profiles are those connected to purchasing, innovation, partnerships, commercialization, research operations, and product evaluation. Since the event is centered on biotech innovation, it is important to target both science-led and business-led roles.
Best job titles to target:
- Head of Innovation
- Director, Business Development
- VP, Strategic Partnerships
- Alliance Manager
- External Innovation Lead
- R&D Director
- Scientific Director
- Lab Operations Manager
- Procurement Manager, Life Sciences
- Product Manager, Biotechnology
- Market Development Manager
- Clinical Research Director
- Commercialization Manager
- Technology Transfer Officer
- Investment Director / VC Partner
- Portfolio Manager, Life Sciences
Best industry categories to use:
- Biotechnology
- Pharmaceuticals
- Medical Devices
- Health, Wellness & Fitness
- Research
- Hospital & Health Care
- Information Services
- Computer Software
- Management Consulting
- Venture Capital & Private Equity
- Environmental Services
- Renewables & Environment
- Education Management
- Higher Education
- Professional Training & Coaching
The event type is important because buyer intent changes based on the format. For Bio Innovations Europe 2026, the most valuable formats are likely to include conference sessions, exhibition booths, partnering meetings, startup showcases, investor meetings, and technical presentations. A buyer list from this event should be treated as a mixed ecosystem of commercial buyers, scientific decision-makers, and partnership seekers.
6️⃣ Estimated attendance / expected footfall
Estimated attendance: 2,000 to 6,000 total delegates is a reasonable working range for a specialized biotech innovation event in Europe, unless the event is co-located with a major expo or large congress, in which case numbers could rise much higher.
The quality of the audience is more important than raw footfall. Even a smaller event can produce excellent list value if it includes:
- Decision-makers from biotech and pharma
- Lab and procurement leaders
- Investors and corporate development teams
- University research and technology-transfer stakeholders
- Vendors and service providers with real buying power
For attendee-list monetization, events like this are usually strongest when you segment by role: business leaders, technical leaders, investment professionals, and service buyers.
7️⃣ Key focus areas & buyer engagement
Likely focus areas at Bio Innovations Europe 2026:
- Biotech product development and pipeline innovation
- Drug discovery and translational research
- Diagnostics and precision medicine
- Genomics, proteomics, and bioinformatics
- Industrial biotech and biomanufacturing scale-up
- Lab automation, instrumentation, and digital workflows
- Clinical research and contract services
- Startup funding, commercialization, and investor partnering
- Sustainability-focused biotech applications
- Cross-border collaboration and market expansion
Best buyer engagement angles:
- Partnership-driven outreach instead of generic event promotion
- Targeted messages around innovation sourcing, not just attendance
- Role-based segmentation for scientific, commercial, and procurement audiences
- Industry-specific messaging for pharma, diagnostics, tools, and platform technologies
- Lead generation value for exhibitors, sponsors, and solution providers
The strongest pitch is usually: “We can help you reach biotech and life-sciences decision-makers actively involved in innovation, R&D, partnerships, procurement, and commercialization.”
8️⃣ Client-product fit note
To identify the best buyers for this event, I need your client’s website or a short description of the product/service. The ideal buyer list changes significantly based on what your client sells.
Examples:
- If your client sells lab equipment, consumables, or instruments, target lab managers, procurement heads, R&D directors, and biotech operations leaders.
- If your client sells software or digital platforms, target innovation leaders, data teams, bioinformatics heads, and technical directors.
- If your client sells CDMO, CRO, or research services, target business development heads, alliance managers, and sourcing teams.
- If your client sells funding, advisory, or legal services, target founders, investors, commercialization teams, and tech-transfer offices.
- If your client sells clinical or diagnostics solutions, target clinical affairs, medical affairs, product leaders, and hospital/lab buyers.
Once you share the client website, I can refine this into a much sharper list of buyer companies and the exact job titles most likely to convert.
9️⃣ Final recommendation
Bio Innovations Europe 2026 is a strong global-to-European B2B event for attendee-list generation, especially for clients selling into biotechnology, pharma, life sciences, diagnostics, lab operations, research services, software, and innovation partnerships.
It is best approached as a high-intent scientific and commercial networking event, where the most valuable contacts are usually the people who influence buying, partnership, and research decisions rather than general attendees.
Overall lead quality score for B2B attendee-list sales: 8.5/10
Best segments to collect: biotech founders, R&D leaders, innovation heads, alliance managers, business development teams, procurement managers, lab operations leaders, investors, and university commercialization contacts.
Please share your client website so I can review the product and give you the best buyer targets based on exact fit.
Data sheet
| Event Name | BIO-Europe 2026 |
| Event Date | 10 June 2026 – 11 June 2026 |
| Event Status | Upcoming |
| Venue | Fokker Terminal, The Hague, Netherlands (User-supplied detail; conflicts with city/region/country supplied and requires organizer confirmation) |
| City | Copenhagen (User-supplied detail; conflicts with venue supplied) |
| State / Region | Capital Region of Denmark (User-supplied detail; requires organizer confirmation) |
| Country | Denmark (User-supplied detail; conflicts with venue supplied) |
| Organizer | Organizer for the 2026 edition not publicly confirmed in the materials reviewed. Historical BIO-Europe series organizer: EBD Group / Informa Connect (Historical / prior-year evidence) |
| Official Event Website | BIO-Europe brand pages require 2026 edition confirmation at research date |
| Event Type | B2B biotechnology and life sciences partnering conference / commercial networking event |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Business Services |
| Audience Reach | Global, based on the BIO-Europe brand’s historical international partnering focus |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer for the 2026 edition. |
| Attendance Data Reliability | Low for current-year quantified metrics; medium for historical event format and attendee profile |
| Main Purpose of Event | Business development, licensing, partnering, investment meetings, R&D collaboration, and commercialization across biotech, biopharma, platform technology, and life sciences services |
BIO-Europe is widely recognized as a high-value life sciences partnering format that typically brings together biopharma companies, biotechnology innovators, investors, licensing teams, contract research and manufacturing providers, and ecosystem partners for structured one-to-one meetings and market-facing discussion. Based on the historical positioning of the BIO-Europe brand, the commercial emphasis is stronger than a purely academic conference and is centered on partnerships, pipeline evaluation, licensing, alliances, fundraising, and business development.
For lead generation, attendee profiling, and buyer targeting, this event format matters because the highest-value participants are often decision-makers from business development, alliance management, partnering, licensing, R&D strategy, venture investment, corporate innovation, and external sourcing functions. Current-year organizer confirmation is still required for the exact 2026 edition details, especially because the supplied location information is internally inconsistent.
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Biopharma business development teams | Large pharma, specialty pharma, therapeutic developers | Evaluate pipeline assets, licensing opportunities, strategic collaborations | High relevance for biotech platforms, clinical assets, service providers, and data vendors |
| Licensing and alliance management leaders | Pharma, biotech, medtech, translational organizations | Manage deal sourcing, co-development structures, and partnerships | Key targets for partnership outreach and long-cycle deal creation |
| Biotech founders and executive teams | Emerging biotech companies, platform startups, spinouts | Buy services, raise capital, source collaborators, validate market interest | Strong fit for CROs, CDMOs, IP firms, cloud/data vendors, and commercialization advisors |
| R&D and translational medicine leaders | Biotech, pharma, research institutes, therapeutic ventures | Assess scientific collaboration, platform validation, and development support | Relevant for discovery tools, assay providers, lab services, and research software |
| Corporate venture and institutional investors | VC funds, strategic investors, growth investors, family offices | Evaluate funding opportunities and market trends | Useful for startup targeting, deal pipeline mapping, and ecosystem intelligence |
| CDMO / CRO sourcing teams | Biopharma developers, biotech scale-up teams | Source outsourcing partners for discovery, development, analytics, and manufacturing | High-value targets for lab services, manufacturing capacity, and specialized consulting |
| Innovation and external research scouts | Pharma innovation units, corporate strategy teams | Identify platform technologies, startups, and partnership candidates | Important for suppliers offering differentiated IP, enabling technologies, or market intelligence |
| Regional cluster, accelerator, and association leaders | Life sciences clusters, trade bodies, incubators | Support member growth, ecosystem partnerships, and inward investment | Useful connectors for market-entry campaigns and B2B introductions |
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city | Requires confirmation | Not yet verifiable | Supplied inputs mention Copenhagen, while the venue supplied is in The Hague |
| Host state / region | Capital Region of Denmark (user-supplied) | Potentially high if Copenhagen is confirmed | Would typically attract Nordic biotech, pharma, and investor communities |
| Nearby business hubs | Nordic life sciences corridor, Benelux life sciences corridor, major EU biotech hubs | High | Even with location uncertainty, BIO-Europe-style events typically draw senior participants from mature biotech clusters |
| National reach | Country-wide business and research participation from the host nation | Medium to high | Expected if official registration and partnering platform open nationally |
| European reach | UK, Germany, France, Switzerland, Netherlands, Belgium, Nordics, Southern Europe | Very high | Strong historical fit for the BIO-Europe brand |
| International reach | North America, Israel, Asia-Pacific, global investors and service providers | High | Likely for partnering, licensing, and cross-border investment activity |
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | BIO-Europe-branded partnering events historically serve international biotech, biopharma, investor, and service-provider audiences rather than a local exhibition-only audience. |
| European | Secondary reach description | Core participation is likely concentrated across major European life sciences markets. |
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Roche | Global biopharma buyer / partner | Major acquirer and collaborator across therapeutics, diagnostics, and platform technologies | roche.com | Head of Business Development, Licensing Director, Alliance Manager | Prior-Year Participation Evidence |
| Novartis | Global biopharma buyer / partner | Active in external innovation, licensing, partnering, and pipeline expansion | novartis.com | BD Director, Search & Evaluation Lead, External Innovation Manager | Prior-Year Participation Evidence |
| AstraZeneca | Global biopharma buyer / partner | Relevant for therapeutic collaborations, R&D partnerships, and strategic sourcing | astrazeneca.com | VP Business Development, Partnering Director, R&D Alliances Lead | Prior-Year Participation Evidence |
| Bayer | Biopharma / life sciences buyer | Relevant for pharma innovation, collaboration, and platform scouting | bayer.com | Open Innovation Director, Licensing Manager, Venture Lead | Prior-Year Participation Evidence |
| Sanofi | Global biopharma buyer / partner | Important external innovation and licensing participant type for partnering meetings | sanofi.com | Strategic Partnerships Director, BD Lead, Alliance Director | Prior-Year Participation Evidence |
| Merck KGaA | Science and healthcare buyer / partner | Relevant for research platforms, bioprocessing, and strategic scientific collaborations | merckgroup.com | Partnerships Director, R&D Sourcing Lead, Business Development Manager | Prior-Year Participation Evidence |
| Johnson & Johnson Innovation | Strategic innovation / venture buyer | Relevant for startup partnerships, investment, and therapeutic innovation scouting | jnjinnovation.com | Innovation Director, Venture Lead, External Innovation Manager | Prior-Year Participation Evidence |
| Pfizer | Global biopharma buyer / partner | Potential buyer of assets, collaborations, research services, and platform technologies | pfizer.com | BD Director, Search & Evaluation, Partnerships Lead | Prior-Year Participation Evidence |
| BioNTech | Biotech buyer / collaborator | High relevance for platform collaborations, R&D alliances, and manufacturing partnerships | biontech.com | Partnering Director, Alliance Manager, Corporate Development Lead | Prior-Year Participation Evidence |
| Evotec | Drug discovery / R&D services buyer-partner | Relevant for outsourced discovery, strategic alliances, and platform collaboration | evotec.com | SVP Partnerships, BD Director, Strategic Alliances Lead | Prior-Year Participation Evidence |
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | VP Business Development | Business Development | VP | Core deal-maker for licensing, partnerships, and external innovation sourcing |
| 2 | Director of Business Development | Business Development | Director | Frequently owns partner identification and event meeting schedules |
| 3 | Licensing Director | Licensing / Corporate Development | Director | Key for asset evaluation, in-licensing, and strategic pipeline expansion |
| 4 | Alliance Manager | Partnerships / Alliances | Manager to Director | Supports active collaborations and evaluates new strategic partner fit |
| 5 | Head of External Innovation | Innovation / Strategy | Head / Director / VP | Scouts new science, platforms, startups, and collaborative technologies |
| 6 | Corporate Development Director | Corporate Development | Director | Relevant for M&A, strategic investment, and portfolio building |
| 7 | R&D Director | Research & Development | Director | Influences evaluation of scientific platforms, tools, and external studies |
| 8 | Strategic Sourcing Manager | Procurement / Sourcing | Manager | Relevant for CRO, CDMO, lab, software, and outsourced research spend |
| 9 | Managing Partner / Principal | Investment | Partner / Executive | Important for fundraising, syndication, and growth partnerships |
| 10 | CEO / Founder | Executive Office | C-Level | Common in biotech partnering events where strategy, capital, and collaborations are discussed directly |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Biotechnology | Core industry for platform developers, therapeutic innovators, and scientific startups | Partnerships, licensing, discovery services, capital raising |
| 2 | Pharmaceuticals | Large buyer group for pipeline, alliances, and outsourced development | In-licensing, co-development, portfolio expansion |
| 3 | Medical Devices | Relevant where diagnostics, companion tools, and translational health technologies overlap | Strategic collaborations and commercialization partnerships |
| 4 | Hospital & Health Care | Relevant for translational ecosystems, innovation partnerships, and clinical validation networks | Clinical collaboration and innovation sourcing |
| 5 | Research | Covers institutes, translational labs, and scientific organizations | Collaboration sourcing and grant-aligned partnerships |
| 6 | Venture Capital & Private Equity | Important for investor attendance and growth financing dialogue | Fundraising, diligence, portfolio support |
| 7 | Information Technology & Services | Relevant for life sciences software, data platforms, and digital enablement providers | R&D informatics, workflow support, partnership tech |
| 8 | Computer Software | Applicable where AI, data analytics, and scientific software serve life sciences users | Clinical, bioinformatics, or commercialization software outreach |
| 9 | Management Consulting | Advisory firms often support partnering, market access, and transaction strategy | Commercial planning and diligence support |
| 10 | International Trade & Development | Useful for cluster organizations and trade promotion bodies active in biotech expansion | Cross-border market entry and ecosystem partnership support |
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Attendance figure not publicly confirmed by the organizer. | Not Confirmed | No verified 2026 organizer attendance metric identified in reviewed materials | Do not use speculative counts for client commitments |
| Exhibitor / participating company count | Not publicly confirmed for 2026 | Not Confirmed | 2026 edition verification pending | Partnering events may emphasize company profiles more than exhibition booths |
| Buyer count | Not publicly confirmed for 2026 | Not Confirmed | No official buyer-specific metric identified | High-value audience quality is typically more important than volume |
| Speaker count | Not publicly confirmed for 2026 | Not Confirmed | Agenda publication pending or not verified | Use official agenda when available for speaker-led prospecting |
| Historical attendance | Historical series is known for substantial international partnering participation, but no current verified figure is inserted here | Historical / prior-year evidence | BIO-Europe brand positioning and prior event materials | Use only after checking the official 2026 prospectus or registration page |
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Licensing and partnering | Pipeline expansion, asset access, co-development | Pre-booked meetings with BD and alliance teams | Therapeutic assets, platform IP, partnering support, diligence services |
| R&D collaboration | Scientific validation, translational support, research acceleration | Meetings with R&D directors and translational teams | CRO services, assay development, discovery tools, bioinformatics |
| Investment and fundraising | Capital access, syndication, strategic backing | Investor meetings, startup showcases, executive introductions | Investment readiness support, market intelligence, legal and advisory services |
| Drug discovery and development outsourcing | Flexible capacity, specialist expertise, speed to milestone | Target sourcing, procurement, and technical evaluation teams | CRO, CDMO, analytics, regulatory, quality, data platforms |
| Digital and data-enabled life sciences | Faster research workflows, insight generation, collaboration infrastructure | Conversations with innovation, R&D, and IT leadership | Software, AI-enabled analytics, scientific informatics, secure collaboration tools |
| Commercialization and market access strategy | Go-to-market planning, partner identification, evidence strategy | Engage BD, launch strategy, and corporate development functions | Consulting, market access support, channel partnerships, launch analytics |
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | The event format is naturally aligned with partnership-led and high-value B2B biotech conversations. |
| Decision-maker availability | High | BIO-Europe-type events typically attract directors, VPs, founders, and investors rather than junior-only traffic. |
| Data collection potential | Medium | Strong if official partnering, sponsor, speaker, or attendee directory access is obtained; limited if only public pages are used. |
| Apollo targeting potential | Very High | Clear industry, job title, seniority, and geography filters can be built around life sciences partnering roles. |
| Geographic targeting potential | High | European core with global spillover gives strong cluster-based segmentation options. |
| Best outreach approach | High | Use partnership-oriented messaging, buyer pain points, and highly personalized relevance by modality, therapy area, or service capability. |
| Overall lead quality | High | Strong event for premium B2B life sciences prospecting, provided current-year confirmation is obtained before list monetization. |
| Best use case | High | Ideal for attendee list building, buyer profiling, sponsor targeting, partnership outreach, and account-based prospecting. |
| Limitations / risks | Medium | Current-year location, organizer, and attendance metrics require verification before any claim of confirmed attendance or venue-based outreach. |
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Biotechnology; Pharmaceuticals; Medical Devices; Hospital & Health Care; Research; Venture Capital & Private Equity; Information Technology & Services; Computer Software; Management Consulting; International Trade & Development | Focus on the most relevant buyer and partner ecosystems around the event |
| Departments | Business Development; Partnerships; Corporate Development; Research; Operations; Procurement; Strategy; Investment | Narrow contacts to commercially active and decision-influencing teams |
| Seniority | Owner; Founder; C-Level; Partner; VP; Head; Director; Manager | Prioritize event-relevant decision-makers and meeting owners |
| Job titles | VP Business Development; Director Business Development; Licensing Director; Alliance Manager; Head of External Innovation; Corporate Development Director; R&D Director; Strategic Sourcing Manager; Principal; Managing Partner; CEO; Founder | Create direct event-like buyer lists for outreach and ABM |
| Geography | Denmark; Sweden; Norway; Finland; Germany; Switzerland; Netherlands; Belgium; United Kingdom; France; United States; Israel | Capture likely European core plus common global life sciences participants |
| Employee size | 11-50; 51-200; 201-500; 501-1000; 1001-5000; 5001+ | Cover venture-backed biotech through multinational pharma and service providers |
| Keywords | licensing; partnering; external innovation; translational medicine; oncology; biologics; cell therapy; gene therapy; drug discovery; CRO; CDMO; biotech platform; venture | Identify event-like company profiles and functional buying intent |
| Technologies | Use only if relevant to client offering; examples include CRM, lab informatics, cloud data stack, bioinformatics platform tags | Useful for software or data-service targeting |
| Revenue range | Optional: $1M-$10M, $10M-$50M, $50M-$500M, $500M+ | Separate early-stage biotech from mature strategic buyers |
| Company type | Public; Private; Venture-backed; Subsidiary; Investor-backed startup | Tailor outreach by capital structure and procurement maturity |
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| Informa Connect BIO-Europe page | Official organizer brand page | Historical BIO-Europe positioning, partnering format, and life sciences market focus | High for brand positioning; current 2026 edition details require confirmation |
| EBD Group BIO-Europe archive / event page | Official historical series source | Historical organizer association with the BIO-Europe series | High for prior-year evidence |
| Fokker Terminal | Official venue website | Confirmed that the supplied venue is located in The Hague, Netherlands | High |
| Wonderful Copenhagen | Official destination organization | Reference source for Copenhagen as a valid city / regional business hub only; not confirmation of event venue | Medium for destination context only |
| User-supplied event details | Provided input | Start date, end date, city, region, country, and venue supplied for draft profiling | Low until matched to official 2026 event materials |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to BIO-Europe 2026 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.